Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Salubris Pharma Licenses Sintanovo’s Peripherally Restricted KOR Agonist STC007 for Pruritus and Pain Across Greater China

Fineline Cube Mar 30, 2026
Company Deals

China’s Largest Healthcare M&A Fund Acquires Pediatrix Therapeutics, Bolstering Pediatric Specialty Pharma Portfolio

Fineline Cube Mar 30, 2026
Company Deals

Insilico Medicine and Eli Lilly Forge $2.75B AI Drug Discovery Partnership, Centered on Best-in-Class Oral Therapeutic

Fineline Cube Mar 30, 2026
Company Deals

Novartis to Acquire Excellergy for Up to $2 Billion, Adding Next-Gen Anti-IgE Antibody Exl-111 to Immunology Pipeline

Fineline Cube Mar 30, 2026
Company Deals

Huahai Pharma and Almirall Strike $340M Monoclonal Antibody Licensing Deal Targeting Dermatology and Beyond

Fineline Cube Mar 30, 2026
Policy / Regulatory

China State Council Mandates Long-Term Care Insurance System – 0.3% Contribution Rate Targets Severe Disability Coverage Within Three Years

Fineline Cube Mar 26, 2026
Company Drug

Hansoh Pharma’s Uplizna Gains Third NMPA Approval in China for Generalized Myasthenia Gravis, Expanding CD19 Antibody Franchise

Fineline Cube Mar 30, 2026
Company Drug

Huadong Medicine’s YY001 Becomes World’s First Recombinant Botulinum Toxin Approved in China for Glabellar Lines

Fineline Cube Mar 30, 2026
Company Drug

Gan & Lee Pharmaceuticals Secures Pakistan Approval for Insulin Glargine Cartridge

Fineline Cube Apr 3, 2025

Gan & Lee Pharmaceuticals (SHA: 603087) has announced the receipt of marketing approval for its...

Company Drug

Biogen’s BIIB080 Receives FDA Fast Track Designation for Alzheimer’s

Fineline Cube Apr 3, 2025

US-based Biogen Inc. (NASDAQ: BIIB) announced that it has received Fast Track designation (FTD) from...

Policy / Regulatory

NMPA Reduces Influenza Vaccine Batch Release Time to 45 Working Days

Fineline Cube Apr 3, 2025

The National Medical Products Administration (NMPA) has issued a notification reducing the time limit for...

Company Deals

Pfizer and Flagship Pioneering Collaborate on AI-Driven Drug Development

Fineline Cube Apr 3, 2025

US pharmaceutical giant Pfizer Inc. (NYSE: PFE) has entered into a collaboration agreement with Flagship...

Company Deals

Nurix Therapeutics Expands Sanofi Partnership with Undisclosed TPD Program

Fineline Cube Apr 3, 2025

US-based targeted protein degradation (TPD) specialist Nurix Therapeutics, Inc. (NASDAQ: NRIX) announced an expanded partnership...

Company

Jiangxi Rimag Lists CT Chest Lesion Data on Shanghai Data Exchange

Fineline Cube Apr 3, 2025

China-based medical imaging expert Jiangxi Rimag Group Co., Ltd (HKG: 2522) has announced the successful...

Company Drug

Novartis’ Fabhalta Approved in China for C3 Glomerulopathy

Fineline Cube Apr 3, 2025

Novartis’ (NYSE: NVS) Fabhalta (iptacopan) has received approval from China’s National Medical Products Administration (NMPA)...

Company Drug

Shionogi Submits Rolling NDA for Ensitrelvir in US for COVID-19 Prophylaxis

Fineline Cube Apr 2, 2025

Shionogi announced on April 1, 2025, the initiation of a rolling New Drug Application (NDA)...

Policy / Regulatory

China’s National Health Commission Outlines Key Tasks for Primary Healthcare Reform in 2025

Fineline Cube Apr 2, 2025

The General Office of China’s National Health Commission has issued a notice outlining key tasks...

Company Drug

Pfizer Expands Abrysvo RSV Vaccine Indication to Include Ages 18-59 in EU

Fineline Cube Apr 2, 2025

Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has amended the marketing...

Company Drug Legal / IP

AccurEdit’s ARTbase-A1 Base Editor Authorized by USPTO

Fineline Cube Apr 2, 2025

On April 2, 2025, China-based AccurEdit Therapeutics (Suzhou) Co., Ltd., a specialist in gene editing...

Company Deals

Organon Acquires U.S. Rights to TOFIDENCE from Biogen

Fineline Cube Apr 2, 2025

Organon (NYSE: OGN) announced today that it has acquired regulatory and commercial rights in the...

Company Drug

Zhifei Bio’s Trivalent Influenza Vaccine Approved for Clinical Trials in China

Fineline Cube Apr 2, 2025

Zhifei Biological (SHE: 300122) announced on April 1, 2025, that its subsidiary Zhifei Longcom has...

Company Deals

ChemPartner Plans Share Issuance to Raise Up to 316.3 Million Yuan

Fineline Cube Apr 2, 2025

On April 2, 2025, ChemPartner Pharmatech (SHE: 300149) announced plans to issue shares to a...

Company Deals Medical Device

Peijia Medical and DSM-Firmenich Collaborate on Polymer Heart Valve Innovation

Fineline Cube Apr 2, 2025

Peijia Medical Technology (Suzhou) Co., Ltd. today held a strategic innovation cooperation signing ceremony and...

Company Drug

Henlius and Organon’s HLX11 Biosimilar Clears EMA Validation Hurdle

Fineline Cube Apr 2, 2025

Shanghai Henlius Biotech, Inc. (HKG: 2696) and Organon (NYSE: OGN) announced that the European Medicines...

Company Drug

Huadong Medicine’s Semaglutide Injection Accepted for Review by China’s NMPA

Fineline Cube Apr 2, 2025

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that the National Medical Products Administration (NMPA)...

Company Deals

Medtronic Partners with Methinks AI to Enhance Stroke Care in Emerging Markets

Fineline Cube Apr 2, 2025

Medtronic announced a strategic partnership with Methinks AI, a leading provider of AI-driven radiological triage...

Company Drug

Hengrui Pharmaceuticals Secures Clinical Trial Approval for HRS-9813 in IPF

Fineline Cube Apr 2, 2025

Hengrui Pharmaceuticals (SHA: 600276) announced on April 1, 2025, that its HRS-9813 capsule has received...

Company Medical Device

Sino Medical Sciences Secures Malaysian Approval for Coronary Balloon Catheter

Fineline Cube Apr 1, 2025

China-based Sino Medical Sciences Technology Inc. (SHA: 688108) has announced receiving marketing approval in Malaysia...

Posts pagination

1 … 161 162 163 … 643

Recent updates

  • Salubris Pharma Licenses Sintanovo’s Peripherally Restricted KOR Agonist STC007 for Pruritus and Pain Across Greater China
  • China’s Largest Healthcare M&A Fund Acquires Pediatrix Therapeutics, Bolstering Pediatric Specialty Pharma Portfolio
  • Hansoh Pharma’s Uplizna Gains Third NMPA Approval in China for Generalized Myasthenia Gravis, Expanding CD19 Antibody Franchise
  • Insilico Medicine and Eli Lilly Forge $2.75B AI Drug Discovery Partnership, Centered on Best-in-Class Oral Therapeutic
  • Huadong Medicine’s YY001 Becomes World’s First Recombinant Botulinum Toxin Approved in China for Glabellar Lines
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Salubris Pharma Licenses Sintanovo’s Peripherally Restricted KOR Agonist STC007 for Pruritus and Pain Across Greater China

Company Deals

China’s Largest Healthcare M&A Fund Acquires Pediatrix Therapeutics, Bolstering Pediatric Specialty Pharma Portfolio

Company Drug

Hansoh Pharma’s Uplizna Gains Third NMPA Approval in China for Generalized Myasthenia Gravis, Expanding CD19 Antibody Franchise

Company Deals

Insilico Medicine and Eli Lilly Forge $2.75B AI Drug Discovery Partnership, Centered on Best-in-Class Oral Therapeutic

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.